These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Multiple System Atrophy - State of the Art. Laurens B; Vergnet S; Lopez MC; Foubert-Samier A; Tison F; Fernagut PO; Meissner WG Curr Neurol Neurosci Rep; 2017 May; 17(5):41. PubMed ID: 28378233 [TBL] [Abstract][Full Text] [Related]
10. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Jellinger KA Mov Disord; 2014 Dec; 29(14):1720-41. PubMed ID: 25297524 [TBL] [Abstract][Full Text] [Related]
11. Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy. Bassil F; Monvoisin A; Canron MH; Vital A; Meissner WG; Tison F; Fernagut PO Mov Disord; 2015 Nov; 30(13):1802-12. PubMed ID: 26260627 [TBL] [Abstract][Full Text] [Related]
12. Multiple system atrophy - a clinicopathological update. Jellinger KA Free Neuropathol; 2020 Jan; 1():. PubMed ID: 37283673 [TBL] [Abstract][Full Text] [Related]
13. A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of α-synuclein oligomers and phosphorylated α-synuclein aggregates. Yamaguchi H; Nishimura Y; Matsuse D; Sekiya H; Masaki K; Tanaka T; Saiga T; Harada M; Kira YI; Dickson DW; Fujishima K; Matsuo E; Tanaka KF; Yamasaki R; Isobe N; Kira JI Brain Behav Immun; 2024 Jul; ():. PubMed ID: 38986725 [TBL] [Abstract][Full Text] [Related]
14. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733 [TBL] [Abstract][Full Text] [Related]
15. Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. Mavroeidi P; Arvanitaki F; Karakitsou AK; Vetsi M; Kloukina I; Zweckstetter M; Giller K; Becker S; Sorrentino ZA; Giasson BI; Jensen PH; Stefanis L; Xilouri M Acta Neuropathol; 2019 Sep; 138(3):415-441. PubMed ID: 31011860 [TBL] [Abstract][Full Text] [Related]
16. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. Bassil F; Guerin PA; Dutheil N; Li Q; Klugmann M; Meissner WG; Bezard E; Fernagut PO Mov Disord; 2017 Aug; 32(8):1230-1239. PubMed ID: 28556404 [TBL] [Abstract][Full Text] [Related]
17. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy. Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813 [TBL] [Abstract][Full Text] [Related]
19. Understanding the Role of CDH4 in Multiple System Atrophy Brain. Isik FI; Katzeff JS; Fu Y; Kim WS J Parkinsons Dis; 2023; 13(8):1303-1311. PubMed ID: 38143373 [TBL] [Abstract][Full Text] [Related]
20. Clinical overview of the synucleinopathies. Martí MJ; Tolosa E; Campdelacreu J Mov Disord; 2003 Sep; 18 Suppl 6():S21-7. PubMed ID: 14502652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]